Shore Neal D, Cookson Michael S, Efstathiou Eleni
Carolina Urologic Research Center, Myrtle Beach, SC 29572, USA.
The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Future Oncol. 2024 Dec;20(40):3351-3354. doi: 10.1080/14796694.2024.2418801. Epub 2024 Nov 18.
In this podcast discussion, we review the landscape of androgen deprivation therapies (ADT) for the treatment of advanced prostate cancer. Prior to 2020, available ADT options to achieve chemical castration included gonadotropin-releasing hormone receptor agonists (e.g., leuprolide) and antagonists (e.g., degarelix) administered via muscular or subcutaneous injection. In 2020, the once-daily oral gonadotropin-releasing hormone antagonist, relugolix, received US regulatory approval for the treatment of advanced prostate cancer based on results from the Phase III HERO trial. In this podcast, we also discuss the primary efficacy and safety results of this trial, and key points for providers and patients to consider as they discuss the different ADT options.
在本次播客讨论中，我们回顾了用于治疗晚期前列腺癌的雄激素剥夺疗法（ADT）的情况。在2020年之前，实现化学去势的可用ADT选项包括通过肌肉注射或皮下注射给药的促性腺激素释放激素受体激动剂（如亮丙瑞林）和拮抗剂（如地加瑞克）。2020年，每日一次口服促性腺激素释放激素拮抗剂relugolix基于III期HERO试验的结果获得了美国监管机构批准，用于治疗晚期前列腺癌。在本次播客中，我们还讨论了该试验的主要疗效和安全性结果，以及医疗服务提供者和患者在讨论不同ADT选项时需要考虑的关键点。
